Recombinant human growth hormone in patients with HIV-associated wasting: A randomized, placebo-controlled trial

Morris Schambelan, Kathleen Mulligan, Carl Grunfeld, Eric S. Daar, Anthony LaMarca, Donald P. Kotler, Jack Wang, Samuel A. Bozzette, James B. Breitmeyer, A. Hurley, K. Javaly, E. S. Daar, J. Pitt, C. Grunfeld, M. Pang, A. E. Heald, K. W. Shipp, D. Pearce, K. Sova, P. PateS. L. Boswell, T. Flynn, B. Polsky, L. Haverstick, M. M. Rothkopf, D. L. Bliffen, R. Rosenfeld, D. P. Kotler, R. N. Pierson, J. Wang, G. Winson, K. Mulligan, M. Schambelan, V. Tai, W. M. Bennison, J. B. Breitmeyer, S. M. Kennedy, T. K. Neu, C. E. Robinson, R. J. Schwalbert, A. LaMarca, D. LaMarca, S. A. Bozzette, D. R. Kuritzkes, M. G. Ray, J. W. Mellors, B. E. Balser, J. P. Balser

Research output: Contribution to journalArticle

285 Citations (Scopus)

Abstract

Background: Body wasting, particularly loss of body cell mass, is an increasingly prevalent acquired immunodeficiency syndrome (AIDS)-defining condition and is an independent risk factor for death in patients infected with the human immunodeficiency virus (HIV). Treatment with growth hormone for 7 days resulted in weight gain and nitrogen retention, but the long-term effects of this treatment in patients with HIV-associated wasting are not known. Objective: To evaluate the long-term effect of treatment with growth hormone on weight, body composition, functional performance, and quality of life in patients with HIV-associated wasting. Design: Randomized, double-blind, placebo-controlled, multicenter trial. Setting: Outpatient university and community-based patient care facilities. Patients: 178 HIV-infected patients with a documented unintentional weight loss of at least 10% or weight less than 90% of the lower limit of ideal body weight. Intervention: Patients were randomly assigned to receive either recombinant human growth hormone, 0.1 mg/kg of body weight per day (average dosage, 6 mg/d) (n = 90) or placebo (n = 88) for 12 weeks. Measurements: Weight; body fat, lean body mass, and bone mineral content (measured by dual-energy x-ray absorptiometry); total body water (by deuterium oxide dilution); extracellular water (by sodium bromide dilution); work output (by treadmill exercise); quality of life; and safety of treatment. Results: Treatment with growth hormone resulted in a sustained and statistically significant increase in weight (mean increase ± SD, 1.6 ± 3.7 kg [P < 0.001]) and lean body mass (3.0 ± 3.0 kg [P < 0.001]), accompanied by a decrease in body fat (-1.7 ± 1.7 kg [P < 0.001]). In contrast, in patients receiving placebo, weight (increase, 0.1 ± 3.1 kg), lean body mass (decrease, 0.1 ± 2.0 kg), and body fat (decrease, 0.3 ± 2.2 kg) did not change significantly from baseline. Differences between groups at week 12 were statistically significant (P = 0.011 for body weight and P < 0.001 for lean body mass and body fat). A greater increase in treadmill work output was noted in the group receiving growth hormone (increase, 99 ± 293 kg · m/min) compared with the group receiving placebo (increase, 20 ± 233 kg · m/min) (P = 0.039). Health status (quality of life) scores did not differ between groups at baseline or after treatment. Days of disability and use of medical resources were the same for both groups. Treatment was well tolerated; no significant differences were seen between groups in clinical events, progression of AIDS, CD4+ or CD8+ cell counts, or viral burden. Conclusion: Treatment with growth hormone increases body weight, lean body mass, and treadmill work output and appears to be a safe and potentially effective therapy in patients with HIV-associated wasting.

Original languageEnglish (US)
Pages (from-to)873-882
Number of pages10
JournalAnnals of Internal Medicine
Volume125
Issue number11
DOIs
StatePublished - Jan 1 1996
Externally publishedYes

Fingerprint

Human Growth Hormone
Growth Hormone
Randomized Controlled Trials
Placebos
HIV
Adipose Tissue
Weights and Measures
Therapeutics
Body Weight
Quality of Life
Acquired Immunodeficiency Syndrome
Deuterium Oxide
Ideal Body Weight
Body Water
Body Composition
Viral Load
Bone Density
Health Status
Multicenter Studies
Weight Gain

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Cite this

Schambelan, M., Mulligan, K., Grunfeld, C., Daar, E. S., LaMarca, A., Kotler, D. P., ... Balser, J. P. (1996). Recombinant human growth hormone in patients with HIV-associated wasting: A randomized, placebo-controlled trial. Annals of Internal Medicine, 125(11), 873-882. https://doi.org/10.7326/0003-4819-125-11-199612010-00002
Schambelan, Morris ; Mulligan, Kathleen ; Grunfeld, Carl ; Daar, Eric S. ; LaMarca, Anthony ; Kotler, Donald P. ; Wang, Jack ; Bozzette, Samuel A. ; Breitmeyer, James B. ; Hurley, A. ; Javaly, K. ; Daar, E. S. ; Pitt, J. ; Grunfeld, C. ; Pang, M. ; Heald, A. E. ; Shipp, K. W. ; Pearce, D. ; Sova, K. ; Pate, P. ; Boswell, S. L. ; Flynn, T. ; Polsky, B. ; Haverstick, L. ; Rothkopf, M. M. ; Bliffen, D. L. ; Rosenfeld, R. ; Kotler, D. P. ; Pierson, R. N. ; Wang, J. ; Winson, G. ; Mulligan, K. ; Schambelan, M. ; Tai, V. ; Bennison, W. M. ; Breitmeyer, J. B. ; Kennedy, S. M. ; Neu, T. K. ; Robinson, C. E. ; Schwalbert, R. J. ; LaMarca, A. ; LaMarca, D. ; Bozzette, S. A. ; Kuritzkes, D. R. ; Ray, M. G. ; Mellors, J. W. ; Balser, B. E. ; Balser, J. P. / Recombinant human growth hormone in patients with HIV-associated wasting : A randomized, placebo-controlled trial. In: Annals of Internal Medicine. 1996 ; Vol. 125, No. 11. pp. 873-882.
@article{5c863e828a8747c48e0bb3c3b6e7e912,
title = "Recombinant human growth hormone in patients with HIV-associated wasting: A randomized, placebo-controlled trial",
abstract = "Background: Body wasting, particularly loss of body cell mass, is an increasingly prevalent acquired immunodeficiency syndrome (AIDS)-defining condition and is an independent risk factor for death in patients infected with the human immunodeficiency virus (HIV). Treatment with growth hormone for 7 days resulted in weight gain and nitrogen retention, but the long-term effects of this treatment in patients with HIV-associated wasting are not known. Objective: To evaluate the long-term effect of treatment with growth hormone on weight, body composition, functional performance, and quality of life in patients with HIV-associated wasting. Design: Randomized, double-blind, placebo-controlled, multicenter trial. Setting: Outpatient university and community-based patient care facilities. Patients: 178 HIV-infected patients with a documented unintentional weight loss of at least 10{\%} or weight less than 90{\%} of the lower limit of ideal body weight. Intervention: Patients were randomly assigned to receive either recombinant human growth hormone, 0.1 mg/kg of body weight per day (average dosage, 6 mg/d) (n = 90) or placebo (n = 88) for 12 weeks. Measurements: Weight; body fat, lean body mass, and bone mineral content (measured by dual-energy x-ray absorptiometry); total body water (by deuterium oxide dilution); extracellular water (by sodium bromide dilution); work output (by treadmill exercise); quality of life; and safety of treatment. Results: Treatment with growth hormone resulted in a sustained and statistically significant increase in weight (mean increase ± SD, 1.6 ± 3.7 kg [P < 0.001]) and lean body mass (3.0 ± 3.0 kg [P < 0.001]), accompanied by a decrease in body fat (-1.7 ± 1.7 kg [P < 0.001]). In contrast, in patients receiving placebo, weight (increase, 0.1 ± 3.1 kg), lean body mass (decrease, 0.1 ± 2.0 kg), and body fat (decrease, 0.3 ± 2.2 kg) did not change significantly from baseline. Differences between groups at week 12 were statistically significant (P = 0.011 for body weight and P < 0.001 for lean body mass and body fat). A greater increase in treadmill work output was noted in the group receiving growth hormone (increase, 99 ± 293 kg · m/min) compared with the group receiving placebo (increase, 20 ± 233 kg · m/min) (P = 0.039). Health status (quality of life) scores did not differ between groups at baseline or after treatment. Days of disability and use of medical resources were the same for both groups. Treatment was well tolerated; no significant differences were seen between groups in clinical events, progression of AIDS, CD4+ or CD8+ cell counts, or viral burden. Conclusion: Treatment with growth hormone increases body weight, lean body mass, and treadmill work output and appears to be a safe and potentially effective therapy in patients with HIV-associated wasting.",
author = "Morris Schambelan and Kathleen Mulligan and Carl Grunfeld and Daar, {Eric S.} and Anthony LaMarca and Kotler, {Donald P.} and Jack Wang and Bozzette, {Samuel A.} and Breitmeyer, {James B.} and A. Hurley and K. Javaly and Daar, {E. S.} and J. Pitt and C. Grunfeld and M. Pang and Heald, {A. E.} and Shipp, {K. W.} and D. Pearce and K. Sova and P. Pate and Boswell, {S. L.} and T. Flynn and B. Polsky and L. Haverstick and Rothkopf, {M. M.} and Bliffen, {D. L.} and R. Rosenfeld and Kotler, {D. P.} and Pierson, {R. N.} and J. Wang and G. Winson and K. Mulligan and M. Schambelan and V. Tai and Bennison, {W. M.} and Breitmeyer, {J. B.} and Kennedy, {S. M.} and Neu, {T. K.} and Robinson, {C. E.} and Schwalbert, {R. J.} and A. LaMarca and D. LaMarca and Bozzette, {S. A.} and Kuritzkes, {D. R.} and Ray, {M. G.} and Mellors, {J. W.} and Balser, {B. E.} and Balser, {J. P.}",
year = "1996",
month = "1",
day = "1",
doi = "10.7326/0003-4819-125-11-199612010-00002",
language = "English (US)",
volume = "125",
pages = "873--882",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "11",

}

Schambelan, M, Mulligan, K, Grunfeld, C, Daar, ES, LaMarca, A, Kotler, DP, Wang, J, Bozzette, SA, Breitmeyer, JB, Hurley, A, Javaly, K, Daar, ES, Pitt, J, Grunfeld, C, Pang, M, Heald, AE, Shipp, KW, Pearce, D, Sova, K, Pate, P, Boswell, SL, Flynn, T, Polsky, B, Haverstick, L, Rothkopf, MM, Bliffen, DL, Rosenfeld, R, Kotler, DP, Pierson, RN, Wang, J, Winson, G, Mulligan, K, Schambelan, M, Tai, V, Bennison, WM, Breitmeyer, JB, Kennedy, SM, Neu, TK, Robinson, CE, Schwalbert, RJ, LaMarca, A, LaMarca, D, Bozzette, SA, Kuritzkes, DR, Ray, MG, Mellors, JW, Balser, BE & Balser, JP 1996, 'Recombinant human growth hormone in patients with HIV-associated wasting: A randomized, placebo-controlled trial', Annals of Internal Medicine, vol. 125, no. 11, pp. 873-882. https://doi.org/10.7326/0003-4819-125-11-199612010-00002

Recombinant human growth hormone in patients with HIV-associated wasting : A randomized, placebo-controlled trial. / Schambelan, Morris; Mulligan, Kathleen; Grunfeld, Carl; Daar, Eric S.; LaMarca, Anthony; Kotler, Donald P.; Wang, Jack; Bozzette, Samuel A.; Breitmeyer, James B.; Hurley, A.; Javaly, K.; Daar, E. S.; Pitt, J.; Grunfeld, C.; Pang, M.; Heald, A. E.; Shipp, K. W.; Pearce, D.; Sova, K.; Pate, P.; Boswell, S. L.; Flynn, T.; Polsky, B.; Haverstick, L.; Rothkopf, M. M.; Bliffen, D. L.; Rosenfeld, R.; Kotler, D. P.; Pierson, R. N.; Wang, J.; Winson, G.; Mulligan, K.; Schambelan, M.; Tai, V.; Bennison, W. M.; Breitmeyer, J. B.; Kennedy, S. M.; Neu, T. K.; Robinson, C. E.; Schwalbert, R. J.; LaMarca, A.; LaMarca, D.; Bozzette, S. A.; Kuritzkes, D. R.; Ray, M. G.; Mellors, J. W.; Balser, B. E.; Balser, J. P.

In: Annals of Internal Medicine, Vol. 125, No. 11, 01.01.1996, p. 873-882.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Recombinant human growth hormone in patients with HIV-associated wasting

T2 - A randomized, placebo-controlled trial

AU - Schambelan, Morris

AU - Mulligan, Kathleen

AU - Grunfeld, Carl

AU - Daar, Eric S.

AU - LaMarca, Anthony

AU - Kotler, Donald P.

AU - Wang, Jack

AU - Bozzette, Samuel A.

AU - Breitmeyer, James B.

AU - Hurley, A.

AU - Javaly, K.

AU - Daar, E. S.

AU - Pitt, J.

AU - Grunfeld, C.

AU - Pang, M.

AU - Heald, A. E.

AU - Shipp, K. W.

AU - Pearce, D.

AU - Sova, K.

AU - Pate, P.

AU - Boswell, S. L.

AU - Flynn, T.

AU - Polsky, B.

AU - Haverstick, L.

AU - Rothkopf, M. M.

AU - Bliffen, D. L.

AU - Rosenfeld, R.

AU - Kotler, D. P.

AU - Pierson, R. N.

AU - Wang, J.

AU - Winson, G.

AU - Mulligan, K.

AU - Schambelan, M.

AU - Tai, V.

AU - Bennison, W. M.

AU - Breitmeyer, J. B.

AU - Kennedy, S. M.

AU - Neu, T. K.

AU - Robinson, C. E.

AU - Schwalbert, R. J.

AU - LaMarca, A.

AU - LaMarca, D.

AU - Bozzette, S. A.

AU - Kuritzkes, D. R.

AU - Ray, M. G.

AU - Mellors, J. W.

AU - Balser, B. E.

AU - Balser, J. P.

PY - 1996/1/1

Y1 - 1996/1/1

N2 - Background: Body wasting, particularly loss of body cell mass, is an increasingly prevalent acquired immunodeficiency syndrome (AIDS)-defining condition and is an independent risk factor for death in patients infected with the human immunodeficiency virus (HIV). Treatment with growth hormone for 7 days resulted in weight gain and nitrogen retention, but the long-term effects of this treatment in patients with HIV-associated wasting are not known. Objective: To evaluate the long-term effect of treatment with growth hormone on weight, body composition, functional performance, and quality of life in patients with HIV-associated wasting. Design: Randomized, double-blind, placebo-controlled, multicenter trial. Setting: Outpatient university and community-based patient care facilities. Patients: 178 HIV-infected patients with a documented unintentional weight loss of at least 10% or weight less than 90% of the lower limit of ideal body weight. Intervention: Patients were randomly assigned to receive either recombinant human growth hormone, 0.1 mg/kg of body weight per day (average dosage, 6 mg/d) (n = 90) or placebo (n = 88) for 12 weeks. Measurements: Weight; body fat, lean body mass, and bone mineral content (measured by dual-energy x-ray absorptiometry); total body water (by deuterium oxide dilution); extracellular water (by sodium bromide dilution); work output (by treadmill exercise); quality of life; and safety of treatment. Results: Treatment with growth hormone resulted in a sustained and statistically significant increase in weight (mean increase ± SD, 1.6 ± 3.7 kg [P < 0.001]) and lean body mass (3.0 ± 3.0 kg [P < 0.001]), accompanied by a decrease in body fat (-1.7 ± 1.7 kg [P < 0.001]). In contrast, in patients receiving placebo, weight (increase, 0.1 ± 3.1 kg), lean body mass (decrease, 0.1 ± 2.0 kg), and body fat (decrease, 0.3 ± 2.2 kg) did not change significantly from baseline. Differences between groups at week 12 were statistically significant (P = 0.011 for body weight and P < 0.001 for lean body mass and body fat). A greater increase in treadmill work output was noted in the group receiving growth hormone (increase, 99 ± 293 kg · m/min) compared with the group receiving placebo (increase, 20 ± 233 kg · m/min) (P = 0.039). Health status (quality of life) scores did not differ between groups at baseline or after treatment. Days of disability and use of medical resources were the same for both groups. Treatment was well tolerated; no significant differences were seen between groups in clinical events, progression of AIDS, CD4+ or CD8+ cell counts, or viral burden. Conclusion: Treatment with growth hormone increases body weight, lean body mass, and treadmill work output and appears to be a safe and potentially effective therapy in patients with HIV-associated wasting.

AB - Background: Body wasting, particularly loss of body cell mass, is an increasingly prevalent acquired immunodeficiency syndrome (AIDS)-defining condition and is an independent risk factor for death in patients infected with the human immunodeficiency virus (HIV). Treatment with growth hormone for 7 days resulted in weight gain and nitrogen retention, but the long-term effects of this treatment in patients with HIV-associated wasting are not known. Objective: To evaluate the long-term effect of treatment with growth hormone on weight, body composition, functional performance, and quality of life in patients with HIV-associated wasting. Design: Randomized, double-blind, placebo-controlled, multicenter trial. Setting: Outpatient university and community-based patient care facilities. Patients: 178 HIV-infected patients with a documented unintentional weight loss of at least 10% or weight less than 90% of the lower limit of ideal body weight. Intervention: Patients were randomly assigned to receive either recombinant human growth hormone, 0.1 mg/kg of body weight per day (average dosage, 6 mg/d) (n = 90) or placebo (n = 88) for 12 weeks. Measurements: Weight; body fat, lean body mass, and bone mineral content (measured by dual-energy x-ray absorptiometry); total body water (by deuterium oxide dilution); extracellular water (by sodium bromide dilution); work output (by treadmill exercise); quality of life; and safety of treatment. Results: Treatment with growth hormone resulted in a sustained and statistically significant increase in weight (mean increase ± SD, 1.6 ± 3.7 kg [P < 0.001]) and lean body mass (3.0 ± 3.0 kg [P < 0.001]), accompanied by a decrease in body fat (-1.7 ± 1.7 kg [P < 0.001]). In contrast, in patients receiving placebo, weight (increase, 0.1 ± 3.1 kg), lean body mass (decrease, 0.1 ± 2.0 kg), and body fat (decrease, 0.3 ± 2.2 kg) did not change significantly from baseline. Differences between groups at week 12 were statistically significant (P = 0.011 for body weight and P < 0.001 for lean body mass and body fat). A greater increase in treadmill work output was noted in the group receiving growth hormone (increase, 99 ± 293 kg · m/min) compared with the group receiving placebo (increase, 20 ± 233 kg · m/min) (P = 0.039). Health status (quality of life) scores did not differ between groups at baseline or after treatment. Days of disability and use of medical resources were the same for both groups. Treatment was well tolerated; no significant differences were seen between groups in clinical events, progression of AIDS, CD4+ or CD8+ cell counts, or viral burden. Conclusion: Treatment with growth hormone increases body weight, lean body mass, and treadmill work output and appears to be a safe and potentially effective therapy in patients with HIV-associated wasting.

UR - http://www.scopus.com/inward/record.url?scp=0030319368&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030319368&partnerID=8YFLogxK

U2 - 10.7326/0003-4819-125-11-199612010-00002

DO - 10.7326/0003-4819-125-11-199612010-00002

M3 - Article

C2 - 8967667

AN - SCOPUS:0030319368

VL - 125

SP - 873

EP - 882

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 11

ER -